Skip to main content

Table 1 Baseline characteristics of women with various forms of hypertension during singleton pregnancies

From: Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2)

Characteristic

No anti-hypertensive drug (n = 980)

β-blocker drug (n = 428)

Non-β-blocker drug (n = 188)

β-blocker and non-β-blocker drug (n = 352)

Statistical comparison across groups

Maternal age (yr)

     

Mean (SD)

29.5 (4.9)

29.8 (4.9)

29.2 (5.8)

28.8 (5.6)

p = 0.04

No. (%)

     

   < 20

22 (2.3)

10 (2.3)

8 (4.3)

20 (5.7)

 

   20–35

845 (86.2)

366 (85.5)

146 (77.6)

288 (81.8)

 

   > 35

113 (11.5)

52 (12.2)

34 (18.1)

44 (12.5)

 

No. (%) primigravidae

448 (45.7)

175 (40.9)

83 (44.2)

125 (35.5)

p = 0.008

No. (%) with prior preterm delivery before 34 weeks *

50 (12.8)

33 (20.9)

16 (21.1)

29 (27.4)

p = 0.002

No. (%) with pre-pregnancy diabetes mellitus

42 (4.3)

14 (3.3)

16 (8.5)

6 (1.7)

p = 0.001

No. (%) with renal dysfunction

34 (3.5)

25 (6.0)

22 (11.8)

22 (6.4)

p < 0.0001

No (%) smokers

96 (9.8)

38 (9.1)

17 (9.1)

37 (10.8)

p = 0.9

Mean (SD) pre-pregnancy weight, kg

71.7 (16.4)

71.3 (16.6)

71.2 (18.5)

69.4 (15.9)

p = 0.2

No. (%) according to hypertension type

     

   Gestational hypertension

627 (64.0)

165 (38.6)

33 (17.6)

39 (11.1)

p < 0.001

   Chronic hypertension

229 (23.4)

122 (28.5)

58 (30.9)

50 (14.2)

p < 0.001

   Chronic hypertension plus superimposed preeclampsia

18 (1.8)

22 (5.1)

25 (13.3)

59 (16.8)

p < 0.001

   Isolated preeclampsia

106 (10.8)

119 (27.8)

72 (38.3)

204 (58.0)

p < 0.001

  1. *Excludes all primigravidae